IPSC
Income statement / Annual
Last year (2023), Century Therapeutics, Inc.'s total revenue was $2.24 M,
a decrease of 57.01% from the previous year.
In 2023, Century Therapeutics, Inc.'s net income was -$136.67 M.
See Century Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$2.24 M
|
$5.20 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$13.04 M |
$10.07 M |
$4.58 M |
$1.75 M |
$249,000.00 |
| Gross Profit |
-$10.81 M |
-$4.87 M |
-$4.58 M |
-$1.75 M |
-$249,000.00 |
| Gross Profit Ratio |
-4.84 |
-0.94 |
0 |
0 |
0 |
| Research and Development
Expenses |
$92.71 M
|
$107.17 M
|
$75.65 M
|
$39.68 M
|
$14.27 M
|
| General & Administrative
Expenses |
$34.71 M
|
$31.86 M
|
$19.24 M
|
$9.50 M
|
$5.77 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$34.71 M
|
$31.86 M
|
$19.24 M
|
$9.50 M
|
$5.77 M
|
| Other Expenses |
$21.37 M |
$4.42 M |
$377,000.00 |
$704,000.00 |
$1.21 M |
| Operating Expenses |
$56.07 M |
$139.03 M |
$94.88 M |
$49.18 M |
$20.03 M |
| Cost And Expenses |
$148.78 M |
$139.03 M |
$94.88 M |
$49.18 M |
$20.03 M |
| Interest Income |
$12.68 M |
$2.99 M |
$898,000.00 |
$704,000.00 |
$1.21 M |
| Interest Expense |
$540,000.00 |
$1.11 M |
$1.28 M |
$381,000.00 |
$0.00 |
| Depreciation &
Amortization |
$13.04 M
|
$10.07 M
|
$4.58 M
|
$1.75 M
|
$249,000.00
|
| EBITDA |
-$121.21 M
|
-$119.34 M
|
-$89.92 M
|
-$51.44 M
|
-$19.78 M
|
| EBITDA Ratio |
-54.23 |
-23.33 |
0 |
0 |
0 |
| Operating Income Ratio
|
-65.57
|
-25.74
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$11.75 M
|
$2.99 M
|
-$898,000.00
|
$323,000.00
|
$1.21 M
|
| Income Before Tax |
-$134.79 M |
-$130.84 M |
-$95.78 M |
-$53.58 M |
-$244.77 M |
| Income Before Tax Ratio
|
-60.31
|
-25.17
|
0
|
0
|
0
|
| Income Tax Expense |
$1.88 M |
$91,000.00 |
$43,000.00 |
$1.09 M |
$1.21 M |
| Net Income |
-$136.67 M |
-$130.93 M |
-$95.82 M |
-$54.66 M |
-$245.98 M |
| Net Income Ratio |
-61.15 |
-25.18 |
0 |
0 |
0 |
| EPS |
-2.3 |
-2.27 |
-1.74 |
-1 |
-4.49 |
| EPS Diluted |
-2.3 |
-2.27 |
-1.74 |
-1 |
-4.49 |
| Weighted Average Shares
Out |
$59.31 M
|
$57.76 M
|
$55.01 M
|
$54.82 M
|
$54.82 M
|
| Weighted Average Shares
Out Diluted |
$59.31 M
|
$57.76 M
|
$55.01 M
|
$54.82 M
|
$54.82 M
|
| Link |
|
|
|
|
|
